Treatment Updates in Antineutrophil Cytoplasmic Autoantibodies (ANCA) Vasculitis
Author(s) -
Koyal Jain,
Pankaj Jawa,
Vimal K. Derebail,
Ronald J. Falk
Publication year - 2021
Publication title -
kidney360
Language(s) - English
Resource type - Journals
ISSN - 2641-7650
DOI - 10.34067/kid.0007142020
Subject(s) - vasculitis , medicine , pathogenesis , autoantibody , adverse effect , immunology , microscopic polyangiitis , inflammation , intensive care medicine , disease , antibody
ANCA vasculitis is a small-vessel vasculitis (SVV) resulting in inflammation of small- and medium-sized blood vessels. Since the initial description of SVV, there have been tremendous advances in our understanding of its pathogenesis. Over the last decade, we have made significant progress in understanding the pathogenesis and improving the treatment and prognosis of patients with ANCA vasculitis. Patient and renal survival has improved, and treatment is moving toward individualizing care, minimizing severe adverse events, and preventing relapse. This review focuses on treatment updates in ANCA vasculitis, duration of therapy, and management of relapses. We also describe the existing treatment protocols used at our institution.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom